CAPR logo

Capricor Therapeutics Inc. (CAPR)

$9.06

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on CAPR

Market cap

$526739240

EPS

-2.45

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

0.72237

Price on CAPR

Previous close

$9.42

Today's open

$9.30

Day's range

$8.96 - $9.36

52 week range

$2.96 - $40.37

Profile about CAPR

CEO

Linda Marbn

Employees

160

Headquarters

San Diego, CA

Exchange

Nasdaq Global Select

Shares outstanding

58138989

Issue type

Common Stock

CAPR industries and sectors

Healthcare

Biotechnology & Life Sciences

News on CAPR

Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Capricor (CAPR) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 9/28/2026

news source

GlobeNewsWire • 13 hours ago

news preview

CAPR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Capricor To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Capricor between December 17, 2025 and July 26, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - September 19, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) and reminds investors of the September 28, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

news source

Newsfile Corp • Sep 19, 2026

news preview

CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline

SAN FRANCISCO, Sept. 19, 2026 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP—a national plaintiffs' rights law firm with a premier securities practice group—notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the ongoing securities class action.

news source

GlobeNewsWire • Sep 19, 2026

news preview

Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Capricor Therapeutics, Inc. - CAPR

NEW ORLEANS, Sept. 18, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 28, 2026 to file lead plaintiff applications in a securities class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NasdaqGS: CAPR), if they purchased Capricor securities between December 17, 2025 and July 26, 2026, inclusive (the "Class Period").

news source

PRNewsWire • Sep 19, 2026

news preview

CAPR 10-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28 Deadline

San Francisco, California--(Newsfile Corp. - September 18, 2026) - Hagens Berman Sobol Shapiro LLP-a national plaintiffs' rights law firm with a premier securities practice group-notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the ongoing securities class action. This alert follows the U.S. Food and Drug Administration's (FDA) recent decision to extend the review period for Capricor's Biologics License Application (BLA), underscoring the ongoing regulatory and disclosure scrutiny surrounding the company.

news source

Newsfile Corp • Sep 18, 2026

news preview

CAPR Securities Losses: Capricor Therapeutics Investors with Losses on their Investment are Reminded to Contact BFA Law by September 28 Deadline in Securities Fraud Class Action

Capricor Therapeutics Investors with Losses on their Investment are Reminded to Contact BFA Law by September 28 Deadline in Securities Fraud Class Action

news source

GlobeNewsWire • Sep 18, 2026

news preview

Kaplan Fox Advises Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) of an Upcoming Securities Class Action Deadline on September 28, 2026

NEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the “Class Period”).

news source

GlobeNewsWire • Sep 18, 2026

news preview

Kaplan Fox Notifies Investors: Deadline to Lead in the Capricor Therapeutics, Inc. (CAPR) Securities Class Action is September 28, 2026

New York, New York--(Newsfile Corp. - September 18, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Capricor and have suffered losses, you may CLICK HERE to contact us.

news source

Newsfile Corp • Sep 18, 2026

news preview

SEPTEMBER 28, 2026 INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - CAPR

San Diego, California--(Newsfile Corp. - September 18, 2026) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, both dates inclusive (the "Class Period"), have until Monday, September 28, 2026 to seek appointment as lead plaintiff of the Capicor class action lawsuit. Captioned Nkamga v.

news source

Newsfile Corp • Sep 18, 2026

news preview

Capricor Therapeutics, Inc. Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending September 28, 2026 Lead Plaintiff Deadline

SAN DIEGO, Sept. 18, 2026 /PRNewswire/ -- Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026 (the "Class Period").

news source

PRNewsWire • Sep 18, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Capricor Therapeutics Inc.

Open an M1 investment account to buy and sell Capricor Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in CAPR on M1